Ischemic heart disease with diabetes
Conditions
Interventions
None listed
Sponsors
Department of Cardiovascular Medicine, Kumamoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Among type 2 diabetic patients who have decided to receive luseogliflozin, those who meet the following criteria are targeted. 1. Patients who have given written consent to participate in this study 2. Persons with ischemic heart disease (angina / asymptomatic myocardial ischemia). 3. Men and women aged 60 to 85 at the time of consent
Exclusion criteria
Exclusion criteria: 1. Those whose symptoms are not stable (acute myocardial infarction / unstable angina) 2. Patients with type 1 diabetes 3. Patients who require glycemic control with insulin preparations (severe ketosis, diabetic coma or precoma, severe infections, before and after surgery, patients with severe trauma, etc.) 4. Patients with severe hepatic dysfunction (liver dysfunction equivalent to Child-Pugh classification C) 5. Patients with IV heart failure symptoms according to NYHA functional classification 6. Patients with BMI less than 18.5 kg / m2, malnourished or starved 7. Patients with a history of hypersensitivity to the study drug 8. Other patients who the investigator deems inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phenotypic changes through ketone body metabolism | — |
Countries
Japan
Contacts
Public ContactArima Yuichiro
IRCMS Developmental Cardiology
Outcome results
None listed